# Integrating accompanying patients into clinical oncology teams: limiting and facilitating factors

**Authors:** Marie-Pascale Pomey, Jesseca Paquette, Monica Iliescu Nelea, Cécile Vialaron, Rim Mourad, Karine Bouchard, Louise Normandin, Marie-Andrée Côté, Mado Desforges, Pénélope Pomey-Carpentier, Israël Fortin, Isabelle Ganache, Catherine Régis, Zeev Rosberger, Danielle Charpentier, Marie-France Vachon, Lynda Bélanger, Michel Dorval, Djahanchah P. Ghadiri, Mélanie Lavoie-Tremblay, Antoine Boivin, Jean-François Pelletier, Nicolas Fernandez, Alain M. Danino, Michèle de Guise

PMC · DOI: 10.1186/s12913-024-10624-w · BMC Health Services Research · 2024-01-30

## TL;DR

This study explores the challenges and successes of integrating patient advisors into cancer care teams in Quebec to improve patient experiences.

## Contribution

The study identifies specific factors that limit or facilitate the integration of accompanying patients into clinical oncology teams.

## Key findings

- Confusion about roles and lack of communication hindered the integration of accompanying patients.
- Creating trust and involving APs in decision-making improved their integration into clinical teams.
- Providing tools like telephone services enhanced the flexibility and effectiveness of accompanying patients.

## Abstract

Since 2018, four establishments in Quebec have been instrumental in implementing the PAROLE-Onco program, which introduced accompanying patients (APs) into healthcare teams to improve cancer patients’ experience. APs are patient advisors who have acquired specific experiential knowledge related to living with cancer, using services, and interacting with healthcare professionals. They are therefore in a unique and reliable position to be able to provide emotional, informational, cognitive and navigational support to patients who are dealing with cancer. We aimed to explore APs’ perspectives regarding the limiting and facilitating factors in terms of how they are integrated into the clinical oncology teams.

A qualitative study based on semi-structured interviews and focus groups was conducted with 20 APs at the beginning of their intervention (T1) and, two years later, during a second data collection (T2). Limiting and facilitating factors of APs’ integration into clinical teams were analyzed in terms of governance, culture, resources and tools.

The limited factors raised by APs to be integrated into clinical teams include the following: confusion about the specific roles played by APs, lifting the egos of certain professionals who feel they are already doing what APs typically do, lack of identification of patient needs, absence of APs in project governance organizational boundaries, and team members' availability. Various communication challenges were also raised, resulting in the program being inadequately promoted among patients. Also mentioned as limiting factors were the lack of time, space and compensation. Creating opportunities for team members to meet with APs, building trust and teaching team members how APs’ activities complement theirs were enhancing factors. Other facilitators include APs being involved in decision-making committees, being leaders in promoting the PAROLE-Onco program to patients and clinical team members and creating opportunities to communicate with team members to help enhance their work and provide feedback to improve patient services. Awareness of APs’ added value for the team and patients is also a key facilitator. Regarding tools, offering accompanying services by telephone allows both patients and APs to benefit from the flexibility they need.

Over time, APs were able to identify optimal factors for successful implementation. Recommendations include APs and professionals working in co-construction on organization, leadership, resources and status factors. This could help catalyze a change in culture within health establishments and allow people dealing with cancer to benefit from the experiential knowledge of other patients within their clinical team.

The online version contains supplementary material available at 10.1186/s12913-024-10624-w.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** MXD1 (MAX dimerization protein 1) [NCBI Gene 4084] {aka BHLHC58, MAD, MAD1}
- **Diseases:** depression (MESH:D003866), anxiety (MESH:D001007), COVID-19 (MESH:D000086382), cancer (MESH:D009369), Breast Cancer (MESH:D001943)
- **Chemicals:** APs (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10826234/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10826234/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC10826234/full.md

---
Source: https://tomesphere.com/paper/PMC10826234